pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Effective Sample Size of each analysis
| Arm | Actual population size |
Effective Sample Size (ESS) | Proportion (%) |
|---|---|---|---|
| Tralokinumab + TCS (base-case analysis) | 137 | 116 | 84.7 |
| Tralokinumab + TCS (sensitivity analysis) | 137 | 124 | 90.5 |
TCS, Topical Corticosteroid
*: For the MAIC analysis, only patients treated with tralokinumab who had complete information for all the matching variables were included.